HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study.

AbstractOBJECTIVE:
The purpose of this double-blind, placebo-controlled study was to evaluate the safety, clinical efficacy and tolerability of imiquimod (2%) in cream to cure external genital warts in males.
METHODS:
Preselected male patients (n=60) ranging between 18 and 50 years of age (mean 24.2) harbouring 558 lesions (mean 9.3) with clinical, histopathological and polymerase chain reaction (PCR) confirmed diagnosis of human papilloma virus (HPV) infection were randomized to two parallel groups. Each patient was allocated a precoded 25g tube, and instructions on how to apply the trial medication to their lesions at home once daily for three consecutive days per week (max. 12 application in 4 weeks). To evaluate the safety, clinical efficacy and tolerance, patients were exa-mined on a weekly basis. Cure was defined as the total elimination of treated warts with PCR, and Southern blot hybridization confirmed negative HPV DNA.
RESULTS:
By the end of the treatment, 40% (24/60) patients and 49.8% (278/558) warts were cured. Breaking the code revealed that imiquimod cream had cured 70% (21/30) patients and 86.8% of warts, while placebo healed three subjects and 28 warts (P=0.0001). Eleven patients (18.3%), predominantly in the imiquimod cream group, experienced mild to moderate, non-objective, drug-related side effects with no dropouts. The study was followed up for 18 months from the first day of the treatment, and among the 26 cured patients, one in the imiquimod cream group and two in the placebo had a relapse after 14 months.
CONCLUSION:
The study demonstrated that 2% imiquimod in cream with mild non-objective side effects is safe, tolerable and significantly more effective than placebo in curing external genital warts in males.
AuthorsT A Syed, S M Hadi, Z A Qureshi, S M Ali, M S Kwah
JournalThe Journal of infection (J Infect) Vol. 41 Issue 2 Pg. 148-51 (Sep 2000) ISSN: 0163-4453 [Print] ENGLAND
PMID11023759 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
CopyrightCopyright 2000 The British Infection Society.
Chemical References
  • Aminoquinolines
  • Cytokines
  • Interferon Inducers
  • imiquimod
Topics
  • Administration, Cutaneous
  • Adolescent
  • Adult
  • Aminoquinolines (administration & dosage, adverse effects, therapeutic use)
  • Condylomata Acuminata (drug therapy)
  • Cytokines (physiology)
  • Double-Blind Method
  • Humans
  • Interferon Inducers (administration & dosage, adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: